Protocol Ledger

NCT05306041 · Phase II · RECRUITING

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Interventional Phase II clinical trial protocol NCT05306041 sponsored by GBG Forschungs in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-02 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05306041
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05306041
Protocol FieldVerified Registry Value
NCT IdentifierNCT05306041
Consolidated Lead SponsorGBG Forschungs
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2023-01-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05306041
Hospital Research SiteLocationSite Profile
Klinikum Chemnitz gGmbHChemnitz, GermanyOpen Hospital Dossier ->
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI